Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

Anna Brown

News Reporter

A little-known — but legal — trade principle is likely to be on pharma companies’ radars as they search for strategies to reduce exposure to President Donald …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

Anna Brown

News Reporter

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

The ‘MAHA report’: Four key takeaways on vaccines, medicine and the pharma industry

FDA adcomm votes unanimously against Pfizer's prostate cancer drug combo

Post-Hoc: AI bio needs to heed the overhyped history of CRISPR

Sanofi makes $470M move for Vigil's Alzheimer's drug, while another asset returns to Amgen

Updated: Eikon Therapeutics cuts staff for the second time in less than two years

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact